March 20th Options Now Available For Encompass Health (EHC)

Encompass Health (EHC) is trading at $102.56; a sell-to-open $100 put (bid $2.35) implies an effective cost basis of $97.65 and a 2.35% cash return (13.41% annualized) with a 59% probability of expiring worthless. A covered-call using the $105 strike (bid $1.80) would produce a 4.13% total return if called at the March 20 expiry (1.76% immediate premium, 10.02% annualized) with a 56% chance of expiring worthless; implied volatilities are ~32% (put) and ~30% (call) versus a 27% trailing 12-month volatility.

Analysis

Market structure: Short-dated option sellers (income strategies, retail covered-call buyers) are direct beneficiaries of EHC’s current option setup: $100 puts yield 2.35% to expiry (Mar 20) and $105 calls yield 1.76%, implying a near-term income trade that monetizes ~30–32% IV vs 27% realized vol. Sellers collect attractive annualized yields (13.4% put, 10.0% call) for <1 month of risk; buyers of direction or tail protection pay a modest vol premium (~5 vol points). Liquidity is concentrated in near-dated strikes +/-2% around $102.56, so flows will concentrate around assignment risk rather than broad market impact.

Risk assessment: Tail risks include sudden Medicare/Medicaid reimbursement changes, adverse regulatory rulings, or a large operational incident at a major facility that could drop shares >10–20% within days — assignment risk is immediate through Mar 20. Near-term (days–weeks) option sellers face gamma risk around earnings/events; medium-term (months) reward depends on fundamentals (occupancy, reimbursement) and could shift realized vol toward implied. Hidden dependency: option sellers implicitly provide financing (buying stock on assignment) and therefore carry balance-sheet exposure if multiple puts across funds get assigned into low-liquidity windows.

Trade implications: Mechanical plays: (1) cash-secured sell $100 Mar20 puts to target effective entry $97.65, size limited to 1–2% portfolio, roll or hedge if EHC trades < $92 (10% drop). (2) For holders, sell $105 Mar20 covered calls to monetize 1.76% premium but cap upside to ~4.1% to expiry; if expecting >8% move, avoid writing. (3) If worried about tails, buy a Mar20 $95/$90 put spread as a cheap hedge to cap losses below ~7–12% for defined cost; size 25–50% of short-put notional.

Contrarian angles: The consensus treats these as vanilla income trades; what’s missed is skew: puts are slightly richer than calls (32% vs 30% IV) and IV > realized by ~5pts — an opportunity to be a systematic short-vol seller on short-dated expiries but only with strict assignment and gap-risk limits. If fundamentals surprise positive (better-than-expected occupancy or reimbursement clarity) EHC can gap >8% and make covered-call sellers under-compensated; conversely, a regulatory shock could leave put sellers assigned into 15–25% drawdowns. Historical parallel: short-dated income trades in healthcare often work when no policy shocks occur, but blow up on tail regulatory events — size accordingly.

Key Decisions for Investors

• Sell cash-secured EHC Mar20 $100 puts to target effective entry $97.65; allocate no more than 1–2% of portfolio notional; set firm exit/roll if EHC < $92 or IV rises >40% (close or roll down to limit assignment losses).
• If already long EHC, sell EHC Mar20 $105 covered calls to collect $1.80 (capping near-term upside at ~4.13%); limit covered-call allocation to ≤50% of long position if expecting material upside (>8%).
• Buy protection: establish a Mar20 $95/$90 put spread (size 25–50% of short-put notional) to limit downside beyond ~7–12% for defined cost; prioritize this if aggregated short-put exposure >1% portfolio.
• Implement a rules-based short-dated vol sell signal: only sell EHC short-dated OTM puts/calls when IV – realized vol ≥ +3 pts and position size <2% portfolio; do not sell naked calls and cap aggregate assignment exposure to 3% portfolio.